CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--TheraGenetics Limited, a personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of central nervous system (CNS) disorders, announced today that Richard Kivel, Chief Executive Officer of TheraGenetics will present at the 2008 Boston Biotech R&D Conference, at 1:00 p.m. (ET) on October 22, 2008 at Harvard Medical School in Boston, Massachusetts. TheraGenetics’ presentation will be moderated by Mike King of Rodman & Renshaw and will provide an overview of the company and its development efforts to bring personalized medicine diagnostics into clinical practice for patients living with diseases of the central nervous system, including schizophrenia, depression, bipolar disorder, Alzheimer's disease and ADHD (attention deficit hyperactivity disorder), through the use of pharmacogenetic tests.
